Microbiome Current Successes

7 active projects, 30 published manuscripts. Their key findings so far:

  • People carrying different IBD genes, such as NOD 2, have different compositions of gut bacteria.  A person’s genes can therefore affect which gut bacteria they host.
  • Different subsets of IBD can be characterized by signature bacterial compositions, defined by risk signature of ~20 microbial families
  • A novel way to study intestinal bacterial metabolism in humans have been identified

Microbiome Phase 4 Progress:

  • Genes affect bacterial composition
  • Viruses play an important role in establishing disease 
  • 20+ families of bacteria implicated in disease progression
  • In 2012, we developed a platform for sharing data between the consortia
  • In 2013, we learned that patients who develop stricturing phenotype have certain microbial populations

Ultimate goals for the consortium-

  • Understand mechanisms by which bacteria, viruses and fungi cause disease in genetically susceptible hosts.  This can lead to new strategies to treat and prevent IBD
  • Identify bacteria and viruses associated with flares:  This will help guide ways to prevent disease relapses by immunization, antibiotics, dietary modification, probiotics, etc.
  • Use bacterial profiles to predict the course of disease in an individual patient with IBD – aggressiveness of disease, risk of complications and response to treatment